Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
RESEARCH TOOLSreports
CDTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.01 - $28.42
Previous CloseN/A
Volume155.01K
Average Volume (3M)111.14K
Market Cap
$244.95M
Enterprise Value-$53.24M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Mar 11, 2025EPS Estimate
-3.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.55
Shares Outstanding10,945,235
10 Day Avg. Volume105,246
30 Day Avg. Volume111,136
Standard Deviation0.23
R-Squared0.05
Alpha-0.00752
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.89
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.85
Enterprise Value/Ebitda1.19
Forecast
1Y Price Target
$39.50Price Target Upside83.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cidara Therapeutics News
PremiumCompany Announcements
Cidara Therapeutics Announces CFO Transition
PremiumCompany Announcements
Cidara Therapeutics Announces Leadership Changes and Appointments
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyCD388 successfully achieved the study's primary efficacy endpoint with a statistically significant reduction in nasal viral load vs. placebo and was overall safe and well-tolerated in the Phase 2a study.
Financial PositionThe 3Q24 cash balance of $127M is sufficient through the Ph2b readout.
Innovative Therapeutic ApproachCidara Therapeutics can change the traditional approach to flu infection with a different therapeutic method than conventional vaccines.
Bears Say
Investment RisksRisks to the investment thesis and price target include clinical trial failure, failure to secure regulatory approval, and a smaller than anticipated commercial opportunity due to market size, competition, or pricing.
Workforce ReductionA workforce reduction of approximately 30% (or 20 employees) in order to focus its resources on developing CD388, its novel DFC candidate for influenza A and B.
---
Ownership Overview
18.54% Insiders
2.08% Mutual Funds
25.96% Other Institutional Investors
51.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CDTX FAQ
What was Cidara Therapeutics’s price range in the past 12 months?
Cidara Therapeutics lowest stock price was $10.01 and its highest was $28.42 in the past 12 months.
What is Cidara Therapeutics’s market cap?
Cidara Therapeutics’s market cap is $244.95M.
When is Cidara Therapeutics’s upcoming earnings report date?
Cidara Therapeutics’s upcoming earnings report date is Mar 11, 2025 which is in 16 days.
How were Cidara Therapeutics’s earnings last quarter?
Cidara Therapeutics released its earnings results on Nov 07, 2024. The company reported -$2.45 earnings per share for the quarter, beating the consensus estimate of -$4.25 by $1.8.
Is Cidara Therapeutics overvalued?
According to Wall Street analysts Cidara Therapeutics’s price is currently Undervalued.
Does Cidara Therapeutics pay dividends?
Cidara Therapeutics does not currently pay dividends.
What is Cidara Therapeutics’s EPS estimate?
Cidara Therapeutics’s EPS estimate is -3.62.
How many shares outstanding does Cidara Therapeutics have?
Cidara Therapeutics has 10,945,235 shares outstanding.
What happened to Cidara Therapeutics’s price movement after its last earnings report?
Cidara Therapeutics reported an EPS of -$2.45 in its last earnings report, beating expectations of -$4.25. Following the earnings report the stock price went up 2.975%.
Which hedge fund is a major shareholder of Cidara Therapeutics?
Currently, no hedge funds are holding shares in CDTX
---
Cidara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (83.38% Upside)
$39.50 (83.38% Upside)
Blogger Sentiment
Bullish
CDTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 389.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.82%
12-Months-Change
Fundamentals
Return on Equity
-203.26%
Trailing 12-Months
Asset Growth
155.77%
Trailing 12-Months
Company Description
Cidara Therapeutics
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
---
CDTX Stock 12 Month Forecast
Average Price Target
$39.50
▲(83.38% Upside)
Technical Analysis
Best Analysts Covering CDTX
1 Year
1 Year Success Rate
15/25 ratings generated profit
1 Year Average Return
+25.69%
reiterated a buy rating 3 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +25.69% per trade.
---